Monograph
C07AA03 - Pindolol |
Propably not porphyrinogenic |
PNP |
Rationale
Beta-blocker. Clinical experience and wo references point to non-porphyrinogenicity.
Chemical description
Beta-receptor blocking agent used in hypertonia, angina pectoris, tachyarrythmia. Eliminated unchanged (30 -40%) and as metabolites. Thunell, patient reports (n=3): tolerated. Andersson, patient report (n=3): tolerated. South African list: use. EPI: safe (betablockers)
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Norway
Luxembourg© NAPOS 2024